A study published in the New England Journal of Medicine has shown that Paxlovid, Pfizer’s miracle pill that was doled out after people got tired of getting boosters, has little to no efficacy in treating COVID.

Study finds Pfizer’s Paxlovid pill does nothing to stop COVID

According to the recent study, which compared people with or without COVID who took nirmatrelvir–ritonavir (i.e., Paxlovid) or a placebo, “The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir–ritonavir and those who received placebo.”

The patients who took Paxlovid, unlike the placebo group, also reported a series of side effects. In this case, side effects were mostly limited to dysgeusia and diarrhea; however, several more severe side effects have been reported in the past, especially when taken alongside other medications.

Put simply, despite being initially reported by the Big Pharma company as being safe and 88% effective, Paxlovid is anything but.

The pill was pushed before efficacy was ever ascertained

What’s concerning about this is that the drug has been pushed by world leaders around the world. For instance, Canadian PM Justin Trudeau was extremely bullish on the drug, securing 1 million treatment courses of the drug at the beginning of 2022. Meanwhile, Biden secured a 20 million for unsuspecting Americans.

This isn’t the first time Paxlovid has been shown to be useless, if not outright harmful, either.

The Gateway Pundit has been reporting of its inefficacy practically since it was first released, and following a major report on its lack of efficacy, Pfizer’s CEO, Albert Bourla, was forced to concede this fact.

“While we are disappointed in the outcome of this particular study, these results do not impact the strong efficacy and safety data we’ve observed in our earlier trial for the treatment of COVID-19 patients at high risk of developing severe illness, and we are pleased to see the growing global use of PAXLOVID in that population,” Bourla said. Before this admissions though, he even went so far as claiming to have taken it despite likely knowing of its inefficacy.

Share this story

Donate now to keep us on the front lines:

Help Keep your News Free

It's crucial we stay in touch

Big Tech wants to censor us, that’s why you need to stay in touch.

YOU MIGHT ALSO LIKE THESE...

Trending News

“It is a scandal:” UK bans puberty blockers for youth under 18, citing a lack of evidence that they’re safe.

Mike Campbell

December 11, 2024

Trending News

Rachel Gilmore tells parliamentary committee that pushback against things like DEI and giving puberty blockers to kids is not only hateful, but it’s helping Russia.

Mike Campbell

December 11, 2024

Trending News

The Department of National Defence says they didn’t fund the survey asking if CAF members have ever purchased “extremism merchandise” such as a Make Canada Great Again hat. But records show the feds gave the same two researchers $50k in 2020 to “support a survey and analysis of the policies that govern hateful conduct and right-wing extremism in the CAF.”

Mike Campbell

December 9, 2024

Trending News

Trudeau tells grieving Indigenous mothers asking for changes to policing that Canada has “built-in colonialism.”

TCS Wire

December 6, 2024

Trending News

Liberals are going after legal firearm owners, again, within one year of the next election.

TCS Wire

December 5, 2024

Trending News

It’s unclear whether this is more embarrassing for the Government of Canada or for academia.

Mike Campbell

December 4, 2024

Want to join the conversation?

Sign up now to be able to like, comment and reply to other members. A full membership to our site includes:

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. You consent to our cookies if you continue to use our website.